Novartis AG is a global healthcare company based in Switzerland that focuses on innovative medicines across a range of therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular disease. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis develops, manufactures, and markets prescription drugs and advanced therapies worldwide.
Think of every patient as a unique garden: their genes are the soil, epigenetics is how the soil has been treated over time (fertilizer, pollution, stress), and the microbiome is the mix of plants and microbes living there. This work is about using data and models to understand how all three together affect health and how people respond to medicines, so treatments can be tailored to each person’s “garden” instead of using one-size-fits-all drugs.
Think of this as giving pharma companies a super-smart digital lab assistant and paperwork robot rolled into one. The assistant can sift through mountains of scientific data to suggest promising new drugs faster, and it can also take over a lot of the routine documentation and admin work that bogs down scientists and health‑care workers.
Think of this as a ‘medical weather forecast’ system powered by AI: it looks at a huge mix of patient data (labs, scans, genetics, history) to predict who is likely to get which disease and which treatment is most likely to work for each person.